← Back to Clinical Trials
Recruiting NCT06515925

NCT06515925 Our Whole Lives Gemini: Virtual Integrative Medical Group Visits for Managing Chronic Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06515925
Status Recruiting
Phase
Sponsor Cambridge Health Alliance
Condition Chronic Pain
Study Type INTERVENTIONAL
Enrollment 212 participants
Start Date 2024-08-01
Primary Completion 2025-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Our Whole Lives (OWL)Low Dose Mindfulness Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 212 participants in total. It began in 2024-08-01 with a primary completion date of 2025-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this research study is to test the efficacy of a non-prescription medicine, web-based platform solution for patients with chronic pain, to improve pain self-management and related outcomes. The main question investigators aim to answer is; would the use of this web-based intervention plus an online group visit compared to control result in better pain-related outcomes and improved pain impact?

Eligibility Criteria

Inclusion Criteria: * English-speaking adults * Over the age of 18 * Experiencing chronic musculoskeletal pain. (Pain may have more than one source; Pain must be non-malignant; Participant must have an average pain intensity of ≥ 4 (1 out of 10) in the past 7 days; Participant must meet the chronic criteria of a pain problem that has persisted at least 3 months, and has resulted in pain on at least half the days in the past 6 months) Exclusion Criteria: * Inability to understand English at a level necessary for informed consent and understanding participation instructions, and participating in the group; * Serious underlying systemic or co-morbid conditions or life event that precludes physical or cognitive ability to participate in the study. * Severe depression * Current mania or psychosis; * Active heroin or cocaine use in the past 3 months * Heavy alcohol use * Known or planned pregnancy

Contact & Investigator

Central Contact

Paula Gardiner

✉ pgardiner@challiance.org

📞 617 806 8735

Principal Investigator

Zev Schuman-Olivier, MD

STUDY DIRECTOR

Cambridge Health Alliance

Frequently Asked Questions

Who can join the NCT06515925 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06515925 currently recruiting?

Yes, NCT06515925 is actively recruiting participants. Contact the research team at pgardiner@challiance.org for enrollment information.

Where is the NCT06515925 trial being conducted?

This trial is being conducted at Malden, United States.

Who is sponsoring the NCT06515925 clinical trial?

NCT06515925 is sponsored by Cambridge Health Alliance. The principal investigator is Zev Schuman-Olivier, MD at Cambridge Health Alliance. The trial plans to enroll 212 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology